Can a Skin Patch Effectively Control Chemotherapy-Induced Nausea, Vomiting?


An upcoming phase 2 study will explore if the transdermal (through the skin) delivery of a drug commonly used to treat nausea and vomiting will result in no nausea, no vomiting and no use of rescue medicines in patients with cancer receiving chemotherapy.

Researchers are launching a trial to investigate a new way of administering Zyprexa (olanzapine), an oral drug that is commonly used to control chemotherapy-induced nausea and vomiting (CINV), called STAR-OLZ, according to the agent’s manufacturer, Straton Therapeutics.

STAR-OLZ is a transdermal (through the skin) method of delivering Zyprexa over the course of five days. It will be studied in the upcoming phase 2 TROPIC-I clinical trial, which will compare a common three-drug regimen used to treat CINV with or without the use of STAR-OLZ in patients receiving cancer treatments that are highly emetic — meaning that they are likely to induce nausea and/or vomiting.

“STAR-OLZ represents the first product to be developed for (Food and Drug Administration [FDA]) approval using the total control primary endpoint, potentially improving outcomes and quality of life for patients,” said Dr. Jamie Oliver, chief medical officer of Starton Therapeutics, in a news release. “Total control is a measure of no nausea, no vomiting, and no rescue medications; existing antiemetics have been approved using a complete response endpoint which only measures vomiting and the need for rescue medications.”

CINV is a common, and sometimes debilitating side effect of chemotherapy treatment that can lead to other complications. Prior research has linked chemotherapy-related nausea with anxiety and depression in patients with cancer, highlighting an urgent need to mitigate these symptoms.

A prior phase 1 in-human bioavailability study showed that STAR-OLZ, which is a patch worn on the skin, had acceptable tolerability and delivered about 60% less drug than when taken orally.

Of note, while the anti-psychotic drug Zyprexa is commonly used to treat CINV in patients with cancer, it is not currently approved by the FDA for any nausea/vomiting indications.

Researchers plan on enrolling approximately 120 patients with cancer who are undergoing highly emetic chemotherapy. TROPIC-I is planned to be conducted in more than 20 cancer centers across the United States.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Image of a woman with brown shoulder-length hair in front of a gray background that says CURE.
Dr. Nitin Ohri in an interview with CURE
Kim Stuck in an interview with CURE
Dr. Sarah Psutka in an interview with CURE at the ASCO Annual Meeting
Kara Morris in an interview with a gray "CURE" background
Related Content